Texas Retina Participating in New Phase III Clinical Trial for Uveal Melanoma
Under the leadership of principal investigator Timothy Fuller, MD, Texas Retina will soon begin enrolling patients in the OptimUM-10 clinical trial, a randomized, Phase III, open-label study of neoadjuvant darovasertib in subjects with primary non-metastatic
read more
Getting to Know Benjamin R. Lin, MD
Board-certified ophthalmologist and retina specialist Benjamin R. Lin, MD, joined Texas Retina in September and cares for patients in our Dallas Main, Dallas North and Plano offices. He came to us from
read more
Welcome Benjamin R. Lin, MD!
Texas Retina is pleased to welcome board-certified ophthalmologist and retina specialist Benjamin R. Lin, MD, to our practice on September 2, 2025. Serving patients in our Dallas Main, Dallas North and Plano
read more
Why Your Appointment May Take Longer Than Anticipated
We often have patients and family members ask why they have to wait or why their appointment is taking so long, especially if they see other patients called back before them. We
read more
Dr. Abbey Delivered On-Demand Presentation About the PHOTON DME Study for ASRS 2025 Meeting
On behalf of the PHOTON study investigators, Texas Retina’s Ashkan M. Abbey, MD, delivered an on-demand presentation titled “Differential Anatomic Response to Aflibercept 8 mg vs 2 mg During Matched Dosing Phase
read more
Dr. Nikisha Kothari Selected as “One to Watch” in Retina Today
Texas Retina’s Dr. Nikisha Kothari has been selected as a “One to Watch” in the July/August issue of Retina Today. This feature highlights individuals identified as future leaders in the field of
read more
July is UV Safety Month — Debunking Seven Common Myths About Sunglasses
When most people think of UV protection, they think of their skin and sunscreen. Did you know that long-term exposure to bright sunlight may also increase your risk of eye disease? July
read more
Initial Results of Phase Ib LOTUS Clinical Trial on Potential New Diabetic Macular Edema Treatment Released
On June 9, 2025, Eluminex Biosciences Limited, a clinical-stage protein therapeutics company, announced positive topline safety, tolerability, and pharmacodynamic data from the multicenter LOTUS Part 1 clinical trial of EB-105 in patients
read more

